NO20064226L - mRNA-profering i spytt, biomarkorer og beslektede fremgangsmater og sett av deler - Google Patents

mRNA-profering i spytt, biomarkorer og beslektede fremgangsmater og sett av deler

Info

Publication number
NO20064226L
NO20064226L NO20064226A NO20064226A NO20064226L NO 20064226 L NO20064226 L NO 20064226L NO 20064226 A NO20064226 A NO 20064226A NO 20064226 A NO20064226 A NO 20064226A NO 20064226 L NO20064226 L NO 20064226L
Authority
NO
Norway
Prior art keywords
saliva
cell
mrna
detecting
biomarkers
Prior art date
Application number
NO20064226A
Other languages
English (en)
Other versions
NO340089B1 (no
Inventor
David T W Wong
Maie A R Stjohns
Yang Li
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO20064226L publication Critical patent/NO20064226L/no
Publication of NO340089B1 publication Critical patent/NO340089B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

En fremgangsmåte for å påvise en biomarkør i spytt der biomarkøren er et ekstracellulært RNA, som omfatter å påvise det ekstracellulære mRNA i det cellefrie spyttet, transkriptomanalyse av spytt omfatter å påvise et transkriptommønster i det cellefrie spyttet, en fremgangsmåte for å påvise genetiske endringer i et organ eller i et gen i organet ved å analysere spyttet, som omfatter å påvise et transkriptommønster og/eller mRNA-profileringen av genet i cellefritt spytt, en fremgangsmåte for å diagnostisere en oral eller systemisk patologi, sykdom eller forstyrrelse hos individet, som omfatter å: påvise en profil for en biomarkør som er assosiert med patologien, sykdommen eller forstyrrelsen, spesielt mRNA og/eller protein, i cellefritt spytt og/eller serum, sett som omfatter identifikator for minst én biomarkør for å utføre minst én av fremgangsmåtene og anvendelse av spyttbiomarkører og/eller serum-mRNA som biomarkører for oral og/eller systemisk patologi, sykdom eller forstyrrelse.
NO20064226A 2004-02-20 2006-09-19 Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt NO340089B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54650704P 2004-02-20 2004-02-20
US54652104P 2004-02-21 2004-02-21
PCT/US2005/005263 WO2005081867A2 (en) 2004-02-20 2005-02-17 Salivary mrna profiling, biomarkers, and related methods and kits of parts

Publications (2)

Publication Number Publication Date
NO20064226L true NO20064226L (no) 2006-11-16
NO340089B1 NO340089B1 (no) 2017-03-06

Family

ID=34915575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064226A NO340089B1 (no) 2004-02-20 2006-09-19 Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt

Country Status (11)

Country Link
US (3) US10072297B2 (no)
EP (1) EP1730304B1 (no)
JP (2) JP4880484B2 (no)
KR (2) KR20070004725A (no)
CN (1) CN1977051B (no)
AU (1) AU2005216095B2 (no)
CA (1) CA2558666C (no)
HK (1) HK1095163A1 (no)
IL (1) IL177579A (no)
NO (1) NO340089B1 (no)
WO (1) WO2005081867A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558666C (en) * 2004-02-20 2015-11-24 The Regents Of The University Of California Salivary mrna profiling, biomarkers, and related methods and kits of parts
US7727715B2 (en) 2004-03-30 2010-06-01 Vector Tobacco, Inc. Global gene expression analysis of human bronchial epithelial cells exposed to cigarette smoke, smoke condensates, or components thereof
CA2574706A1 (en) * 2004-07-21 2006-02-23 The Regents Of The University Of California Salivary transcriptome diagnostics
EP2059813A2 (en) * 2006-06-26 2009-05-20 Technion Research & Development Foundation LTD. Methods and kits for diagnosing cancer
US8110362B2 (en) 2006-10-12 2012-02-07 Niigata University Method for determining a tongue cancer
JP2008295327A (ja) * 2007-05-30 2008-12-11 Fujifilm Corp 口腔扁平上皮癌の検出方法、及び抑制方法
WO2008157501A1 (en) * 2007-06-15 2008-12-24 The Regents Of The University Of California Salivary exon core transcriptome
AU2008276027B2 (en) * 2007-07-16 2014-09-04 California Institute Of Technology Arrays, substrates, devices, methods and systems for detecting target molecules
WO2010011860A1 (en) * 2008-07-23 2010-01-28 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
CA2733246C (en) 2008-08-04 2018-02-20 Institut Clinident Method of evaluating oral cancer risk in human
US20130143747A1 (en) * 2011-12-05 2013-06-06 Myriad Genetics, Incorporated Methods of detecting cancer
US9075060B2 (en) 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
WO2010151789A1 (en) * 2009-06-25 2010-12-29 The Regents Of The University Of California Salivary transcriptomic and microbial biomarkers for pancreatic cancer
EP3865590B1 (en) 2009-09-09 2024-04-10 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
EP3461912B1 (en) 2009-09-09 2022-07-13 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
JP2011072229A (ja) * 2009-09-29 2011-04-14 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた下咽頭がんの診断・治療選択
US8309299B2 (en) * 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012064993A1 (en) 2010-11-10 2012-05-18 Exosome Diagnosties, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
AU2012314515B2 (en) * 2011-09-26 2018-03-15 Preanalytix Gmbh Stabilisation and isolation of extracellular nucleic acids
WO2014031997A1 (en) 2012-08-24 2014-02-27 Yale University System, device and method for high-throughput multi-plexed detection
US10724074B2 (en) 2012-09-25 2020-07-28 Qiagen Gmbh Stabilisation of biological samples
US20140188442A1 (en) * 2012-12-27 2014-07-03 Pearson Education, Inc. System and Method for Selecting Predictors for a Student Risk Model
US20160281133A1 (en) 2013-03-18 2016-09-29 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
EP3447141B1 (en) 2013-03-18 2020-08-05 PreAnalytiX GmbH Stabilisation of biological samples
WO2014182598A1 (en) * 2013-05-06 2014-11-13 Physicians Choice Laboratory Services, Llc Diagnostic assay combining cellular and cell free nucleic acid
EP3064940B1 (en) * 2013-10-28 2019-07-03 Salivatech Co., Ltd. Salivary biomarker for pancreatic cancer
US12027243B2 (en) 2017-02-17 2024-07-02 Hc1 Insights, Inc. System and method for determining healthcare relationships
US20210005324A1 (en) * 2018-08-08 2021-01-07 Hc1.Com Inc. Methods and systems for a health monitoring command center and workforce advisor
GB201417281D0 (en) * 2014-09-30 2014-11-12 Ge Healthcare Uk Ltd Methods and devices relating to the detection of oral cancer biomarkers
CN107407638B (zh) 2014-12-03 2021-01-12 伊索普莱西斯公司 细胞分泌特征的分析和筛选
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
DK3262190T3 (da) 2015-02-24 2021-10-11 Univ Heidelberg Ruprecht Karls Biomarkørpanel til påvisning af cancer
CN106446599A (zh) * 2015-08-11 2017-02-22 中国科学院青岛生物能源与过程研究所 一种筛选婴幼儿龋病的口腔致病性生物标记物的方法
CN108291250B (zh) 2015-11-20 2022-05-27 凯杰有限公司 用于稳定细胞外核酸的已灭菌组合物的制备方法
GB201602210D0 (en) 2016-02-08 2016-03-23 Ucl Business Plc Detection of cancer
DK3538891T3 (da) 2016-11-11 2022-03-28 Isoplexis Corp Sammensætninger og fremgangsmåder til samtidig genomisk, transkriptomisk og proteomisk analyse af enkeltceller
CN110226084A (zh) 2016-11-22 2019-09-10 伊索普莱克西斯公司 用于细胞捕获的系统、装置和方法，以及其制造方法
US20200157637A1 (en) * 2017-05-26 2020-05-21 Board Of Regents, The University Of Texas System Targeting of anaplastic lymphoma kinase in squamous cell carcinoma
CN111226118A (zh) * 2017-10-27 2020-06-02 加利福尼亚大学董事会 用于牙龈炎的唾液细胞外rna生物标记物
WO2019171110A1 (en) * 2018-03-04 2019-09-12 Mazumdar Shaw Medical Foundation Salivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers
EP3671213A1 (en) * 2018-12-20 2020-06-24 Kromat Muszerforgalmazó Kft. In vitro method for the diagnosis of malignant conditions
WO2020128546A1 (en) * 2018-12-20 2020-06-25 Kromat Műszerforgalmazó Kft. A simple, non-invasive method for diagnosing oral cancer
JP2020195314A (ja) * 2019-05-31 2020-12-10 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
JP7373843B2 (ja) 2019-12-19 2023-11-06 国立大学法人東海国立大学機構 感染の原因生物を予測するための予測装置、予測プログラム及び予測方法
CN113985033A (zh) * 2021-10-19 2022-01-28 中山大学附属第八医院（深圳福田） 一种用于诊断骨质疏松症发生肌少症的生物标记物及检测试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511805B1 (en) * 1996-03-15 2003-01-28 The Penn State Research Foundation Methods for detecting papillomavirus DNA in blood plasma and serum
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20020102553A1 (en) 1997-10-24 2002-08-01 University Of Rochester Molecular markers for the diagnosis of alzheimer's disease
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6617112B2 (en) 2000-10-11 2003-09-09 Monsanto Technology Llc Methods for gene array analysis of nuclear runoff transcripts
WO2003009806A2 (en) * 2001-07-25 2003-02-06 Oncomedx Inc. Methods for evaluating pathologic conditions using extracellular rna
CA2558666C (en) * 2004-02-20 2015-11-24 The Regents Of The University Of California Salivary mrna profiling, biomarkers, and related methods and kits of parts

Also Published As

Publication number Publication date
EP1730304B1 (en) 2013-01-02
JP4880484B2 (ja) 2012-02-22
JP5367760B2 (ja) 2013-12-11
KR20130018438A (ko) 2013-02-22
US20140249236A1 (en) 2014-09-04
CN1977051B (zh) 2013-07-17
JP2011229532A (ja) 2011-11-17
NO340089B1 (no) 2017-03-06
HK1095163A1 (en) 2007-04-27
US20080280772A1 (en) 2008-11-13
US10072297B2 (en) 2018-09-11
KR20070004725A (ko) 2007-01-09
EP1730304A4 (en) 2007-10-24
AU2005216095B2 (en) 2009-09-17
CA2558666A1 (en) 2005-09-09
WO2005081867A2 (en) 2005-09-09
IL177579A0 (en) 2006-12-10
US20190040471A1 (en) 2019-02-07
CN1977051A (zh) 2007-06-06
CA2558666C (en) 2015-11-24
WO2005081867A3 (en) 2006-07-06
AU2005216095A1 (en) 2005-09-09
US9983210B2 (en) 2018-05-29
JP2007522819A (ja) 2007-08-16
EP1730304A2 (en) 2006-12-13
IL177579A (en) 2012-03-29

Similar Documents

Publication Publication Date Title
NO20064226L (no) mRNA-profering i spytt, biomarkorer og beslektede fremgangsmater og sett av deler
Drabovich et al. Toward an integrated pipeline for protein biomarker development
WO2010019550A3 (en) Method of identifying disease risk factors
WO2010006048A3 (en) Gene expression profiling for predicting the survivability of prostate cancer subjects
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
ATE508364T1 (de) Diagnoseverfahren für präeklampsie
BRPI0509193B8 (pt) método para diagnosticar doença cervical de alto grau em um paciente, e kit
PT2185937E (pt) Método para ensaiar septicemia em seres humanos
Radzikowska et al. Omics technologies in allergy and asthma research: An EAACI position paper
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2009006323A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2007025044A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
JP2011503547A5 (no)
WO2005042761A3 (en) Biomarkers for amyotrophic lateral sclerosis
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
JP2015505370A5 (no)
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
EA201291228A1 (ru) Биомаркер для детекции высокогорной адаптации и высокогорного отека легких
MX2012014284A (es) Metodos y kits para diagnosticar afecciones relacionadas con hipoxia.
WO2009014987A3 (en) Identification and quantification of biomarkers for evaluating the risk of preterm birth
WO2005116261A3 (en) Rna expression microarrays
ATE449189T1 (de) Diagnose- und prognoseverfahren der nichtalkoholischen steatohepatitis (nash)
WO2010051214A8 (en) Compositions and methods for detecting mutations in jak2 nucleic acid

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees